Search Results for "Retin-A"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Retin-A. Results 61 to 70 of 72 total matches.
See also: tretinoin
Prevention and Treatment of Monkeypox
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
of
monkeypox during an outbreak
Cidofovir (Vistide)
FDA-approved for treatment of cytomegalovirus retinitis ...
An outbreak of monkeypox has recently spread around
the globe and across the US. Updated information
about the current outbreak is available from the CDC.
Lasik and Its Alternatives: An Update
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004 (Issue 1174)
to the corneal endothelium, glaucoma, retinal detachment and cataract formation.
CONCLUSION — LASIK, the most ...
Since the last Medical Letter article on surgical correction of refractive errors (Volume 41, page 122, 1999), some new techniques have been tried and new results have been reported.
ThermaClear for Acne
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007 (Issue 1263)
acnes,
and retinoids such as tretinoin (Retin-A, and others),
adapalene (Differin) and tazarotene ...
The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate inflammatory acne, not severe nodular or severe cystic acne, and it is not meant to be used on blackheads and whiteheads. Two similar devices are already on the market: Zeno, another handheld device that delivers heat to acne lesions, and the Radiancy Clear Touch Lite Acne Clearance System, a larger heat-delivery device.
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
every 1-4 months depending on disease
activity.
Conjunctival hemorrhage, endophthalmitis, retinal ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of neovascular
(wet) age-related macular degeneration (nAMD) and
diabetic macular edema (DME). It is the first drug to
become available in the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available for treatment of
nAMD and DME (see Table 2).
Drugs for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • May 02, 2022 (Issue 1649)
such as serous retinal detachment, retinal
vascular occlusion, and ischemic optic neuropathy
can occur rarely ...
About 60% of men ≥60 years old have clinically
relevant prostatic enlargement due to benign prostatic
hyperplasia (BPH). The goals of treatment are to
decrease lower urinary tract symptoms and to prevent
disease progression and complications such as acute
urinary retention. The American Urologic Association's
guidelines for treatment of BPH were recently updated.
Suvorexant (Belsomra) for Insomnia
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015 (Issue 1463)
doses that were at least
7 times those used in humans found an increased
incidence of retinal atrophy ...
The FDA has approved suvorexant (Belsomra –
Merck), the first orexin receptor antagonist to become
available in the US, for treatment of sleep-onset and/or
sleep-maintenance insomnia.
Drugs for Open-Angle Glaucoma
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
vision can occur. Retinal detachment can also
occur, especially in highly myopic patients. Systemic ...
Glaucoma is a progressive optic neuropathy
associated with increased intraocular pressure
(IOP; normal range 8-22 mm Hg), which is the only
disease-related factor that can be modified. Topical
drugs that lower IOP are the first line of treatment for
open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8 doi:10.58347/tml.2025.1727a | Show Introduction Hide Introduction
Drugs for Common Bacterial Infections in Adults
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017 (Issue 1532)
; delirium; psychosis; vertigo; seizures;
paresthesias; blurred vision and photophobia; retinal detachment ...
Bacterial infections in adults are generally treated
empirically, with the antibiotic covering most, but not
all, of the potential causative pathogens. For some
infections, culture and sensitivity testing can guide
treatment, allowing for use of narrower-spectrum
antibiotics. The recommended dosages and durations
of antibiotic treatment for common respiratory, skin, and
urinary tract infections are listed in Tables 1-3. Infectious
disease experts now recommend shorter treatment
durations for many infections to reduce the development
of antimicrobial resistance and minimize adverse...
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
with
tamoxifen can increase the risk of retinal toxicity.6
Sulfasalazine – The aminosalicylate sulfasalazine ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
resistance/diabetes; retinal changes; optic neuritis indinavir and atazanavir
Emtricitabine Well tolerated ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.